Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets

Report Summary

The global market for musculoskeletal disease is currently approaching $45 billion. The overall 5-year compound annual growth rate (CAGR) is forecasted to be about 5%, bringing the total market to more than $57 billion by 2014.

Rheumatoid arthritis and osteoarthritis currently represent 53% of the total market. The RA market was worth an estimated $9.5 billion in 2009 and should reach nearly $12.5 billion by 2015, while the osteoarthritis segment was valued at $14.5 billion in 2009 and should reach an estimated $19 billion by 2014. For both sectors this represents a compound annual growth rate (CAGR) of 5.6%.

Lupus is an emerging area for development, as outcome measures and understanding of the disease pathology become more refined. This segment was valued at $1.5 billion in 2009 and is projected to reach $2 billion by 2014, a compound annual growth rate (CAGR) of 5.2%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC’s goal in conducting this study was to determine the current status of the musculoskeletal disease (MSD) treatments and assess the growth potential of this area over a 5-year period from 2009 to 2014.

Our key objective was to present a comprehensive analysis of the current pipeline of therapeutics and biomaterials utilized in the treatment of MSDs, analyze the market and forecast for MSD therapeutics and treatments, and outline the key factors that will influence this therapeutic area in the next few years.

Diseases of the musculoskeletal system have plagued a significant portion of the population, and the number of incidence increases as the population ages. There have been many successful therapeutics marketed to date, but there is still room for more effective therapies. Advances in biomaterials are being translated into viable products in the orthobiologics area as well, thus changing the way a number of related disease states are treated. More is being elucidated about these diseases, and this promises to translate into more therapies and market opportunities for a variety of players.

REASONS FOR DOING THIS STUDY

Musculoskeletal disease affects roughly 20% of the population and is a significant factor in overall healthcare expenditure. Diseases such as rheumatoid arthritis, osteoporosis, and osteoarthritis are treated with various drug types, and a large development pipeline of potential new therapies is currently being tested. Clinical success has proven elusive, however, as there are now numerous companies developing novel treatments. This report reviews the programs in development and quantifies the market opportunities in MSDs. This study aims to quantify the direction in which this market is heading and the areas in which opportunities may lie.

SCOPE OF REPORT

The scope of this report focuses on the ethical pharmaceutical segment and biomaterials areas, usually categorized with medical devices. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the segment economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for the time period from 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will also be of interest also to suppliers of products and services to this market area.

INTENDED AUDIENCE

The intended audience for this report is the pharmaceutical and biotechnology diagnostics industries, as well as the medical industry that treats patients in these areas.

METHODOLOGY

BCC presents an analysis by each disease area and the number of current patients. Based on our surveys, we then analyze the potential applications for pharmaceuticals and forecast markets for 2009 and 2014.

Table of Contents

CHAPTER ONE: INTRODUCTION

 

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

METHODOLOGY

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

 

CHAPTER TWO: SUMMARY

 

SUMMARY

 

SUMMARY TABLE GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, THROUGH 2014 ($ MILLIONS)

FIGURE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, 2009 AND 2014 ($ MILLIONS)

CHAPTER THREE: OVERVIEW

TABLE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONIC MEDICAL CONDITIONS (%)

 

FIGURE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONIC MEDICAL CONDITIONS (%)

DEFINITION AND MARKET STRUCTURE

TABLE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, THROUGH 2014 ($ MILLIONS)

 

FIGURE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, 2009 AND 2014 ($ MILLIONS)

DISEASES OF THE BONE

OSTEOPOROSIS

PAGET’S DISEASE

OSTEOMALACIA

RICKETS

OSTEOMYELITIS

AVASCULAR NECROSIS (OSTEONECROSIS)

DISEASES OF THE SKELETAL MUSCLE

MYOPATHY

CHRONIC FATIGUE SYNDROME

FIBROMYALGIA

MUSCULAR DYSTROPHY

DERMATOMYOSITIS

POLYMYOSITIS

RHABDOMYOLYSIS

COMPARTMENT SYNDROME

DISEASES OF THE JOINTS

RHEUMATOID ARTHRITIS (RA)

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Developments

New Treatments

Recent Clinical Trials

Outlook for Disease Area

LUPUS

Causes

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Developments

New Treatments

Recent Clinical Trials

Outlook for Disease Area

GOUT

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Treatments

Recent Clinical Trials

Outlook for Disease Area

JUVENILE IDIOPATHIC ARTHRITIS

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Treatments

Recent Clinical Trials

Outlook for Disease Area

OSTEOARTHRITIS

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Treatments

Recent Clinical Trials

Outlook for Disease Area

PSORIATIC ARTHRITIS

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Treatments

Recent Clinical Trials

Outlook for Disease Area

ANKYLOSING SPONDYLITIS

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

Recent Clinical Trials

Outlook for Disease Area

OSTEOPOROSIS

Epidemiology

Symptoms and Diagnosis

Standard of Treatment

New Treatments

Recent Clinical Trials

Outlook for Disease Area

CHAPTER FOUR: THERAPEUTICS

TABLE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 (%/$ MILLIONS)

 

FIGURE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 ($ MILLIONS)

DMARDS

TABLE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDING BIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONS)

 

FIGURE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDING BIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONS

BIOLOGICS

NSAIDS

TABLE 5 GLOBAL REVENUE OF NSAIDS FOR MSD, 2009 ($ MILLIONS)

 

FIGURE 5 GLOBAL REVENUE OF NSAIDS FOR MSD BY DRUG, 2009 ($ MILLIONS)

CORTICOSTEROIDS

TABLE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009 ($ MILLIONS)

 

FIGURE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009 ($ MILLIONS)

BISPHOSPHONATES

TABLE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($ MILLIONS)

 

FIGURE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($ MILLIONS)

CALCITONINS

TABLE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($ MILLIONS)

 

FIGURE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($ MILLIONS)

ESTROGEN REPLACEMENT THERAPY

SELECTIVE ESTROGEN RECEPTOR MODULATORS

TABLE 9 GLOBAL SERM MARKET FOR MSD, 2009 ($ MILLIONS)

 

PARATHYROID HORMONE

TABLE 10 GLOBAL PTH MARKET FOR MSD ($ MILLIONS)

 

ORTHOBIOLOGICS

BMPS

TABLE 11 GLOBAL BMP MARKET FOR MSD, 2009 ($ MILLIONS)

 

FIGURE 9 GLOBAL BMP MARKET FOR MSD BY COMPANY, 2009 ($ MILLIONS)

PROTEIN THERAPY

GENE THERAPY

CELLULAR THERAPY

SYNTHETIC BONE GRAFT

POLYMERS

COMPOSITE GRAFTS

DEMINERALIZED BONE MATRIX

VISCOSUPPLEMENTATION

TABLE 12 VISCOSUPPLEMENTATION MARKET SHARE BY PRODUCT, 2009 (%)

 

FIGURE 12 VISCOSUPPLEMENTATION MARKET SHARE BY PRODUCT, 2009 (%)

MARKET SIZE AND KEY PLAYERS

TABLE 13 TOP 10 COMPANIES IN MSD MARKET, REVENUE AND ASSOCIATED GLOBAL MARKET SHARE, 2009 ($ MILLIONS/%)

 

FIGURE 13 TOP 10 COMPANIES IN MSD MARKET BY GLOBAL MARKET SHARE, 2009 (%)

MARKET SIZE

KEY PLAYERS

Pfizer

Abbott

J&J

Merck

Amgen

Roche

UCB

BMS

Medtronic

GLOBAL INDUSTRY STRUCTURE

TABLE 14 SWOT ANALYSIS OF MSD MARKET: NSAIDS

 

TABLE 15 SWOT ANALYSIS OF MSD MARKET: BIOLOGICALS

GROWTH DRIVERS

GROWTH OBSTACLES

APPLICATIONS

TABLE 16 GLOBAL PROJECTED MARKET FOR MSD, BY APPLICATION, THROUGH 2014 ($ MILLIONS)

 

FIGURE 12 GLOBAL PROJECTED MARKET FOR MSD, BY APPLICATION, 2006-2014 ($ MILLIONS)

ORTHOBIOLOGICS

TABLE 17 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BY COMPANY, 2009 (%)

 

FIGURE 15 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BY COMPANY, 2009 (%)

AUTOGENOUS BONE GRAFT AND THE BONE GRAFT SUBSTITUTE MARKET

FUSION RATES: ALWAYS ROOM FOR IMPROVEMENT

DRIVERS OF GROWTH IN THE MARKET

SEGMENTS IN THE BONE AND BONE SUBSTITUTE MARKET

FUTURE DISPLACEMENT IN A DYNAMIC SPINE MARKET?

TABLE 18 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BY MATERIAL TYPE, THROUGH 2014 ($ MILLIONS)

 

FIGURE 16 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BY MATERIAL TYPE, 2008-2014 ($ MILLIONS)

MARKET CHALLENGES

HIGH COST OF BMPS

PATENT PROTECTION

BIOCOMPATIBILITY ISSUES

EXISTING MARKET

MEDTRONIC INFUSE

STRYKER OP-1

DEPUY MP52

AVERAGE SELLING PRICE

FUTURE OF THE MARKET

THERAPEUTICS

TABLE 19 PROJECTED MARKET FOR KEY MSD PRODUCTS, THROUGH 2014 ($ MILLIONS)

 

FIGURE 15 PROJECTED MARKET FOR KEY MSD PRODUCTS, 2008-2014 ($MILLIONS)

TABLE 20 TREATMENTS AND MOA

SUMMARY OF COMMON MEDICATIONS

TABLE 21 SIDE EFFECTS

 

TABLE 22 PREVALENCE OF MAJOR MSDS IN MAJOR GLOBAL MARKETS, 2009 (%)

TABLE 23 GLOBAL POTENTIAL MARKET FOR TOTAL MSD, THROUGH 2014 ($ MILLIONS)

TABLE 24 KEY OTC TREATMENTS AND NATURAL PRODUCTS

TABLE 25 DRUGS USED TO TREAT MSD

TABLE 26 LEADING MSD THERAPIES AND COST PER DAY (U.S. DOLLARS)

CHAPTER FIVE: LEGISLATION AND REGULATORY ENVIRONMENT

HEALTHCARE REFORM

COST-BENEFIT ANALYSIS

REIMBURSEMENT AND PRICING

REGULATORY CHALLENGES

BIOSIMILARS

CHAPTER SIX: RELATED DEALS AND PARTNERSHIPS

TABLE 27 VENTURE INVESTMENT IN MSD COMPANIES

 

RELATED DEALS AND …

TABLE 28 RELATED DEALS AND PARTNERSHIPS

 

CHAPTER SEVEN: PIPELINE

TABLE 29 CLINICAL DEVELOPMENT PIPELINE

 

CHAPTER EIGHT: PATENT ANALYSIS

PATENT EXPIRATIONS

ACTEMRA

SIMPONI

KINERET

CIMZIA

NEW PATENTS FILED

TABLE 30 PATENT ANALYSIS

 

TABLE 31 KEY PATENT HOLDERS IN BONE/JOINT DISEASE AREA (NUMBER/%)

FIGURE 19 KEY PATENT HOLDERS IN BONE/JOINT DISEASE MARKET (%)

CHAPTER NINE: COMPANY PROFILES

AB SCIENCE

ABBOTT

ABLYNX, NV

ACCELERON PHARMA

ACTIVE BIOTECH RESEARCH AB

ALDER BIOPHARMACEUTICALS, INC.

ALETHIA BIOTHERAPEUTICS, INC.

AMGEN

ARANA THERAPEUTICS

ARRAY BIOPHARMA

ASTELLAS

ASTION PHARMA A/S

ASTRAZENECA

BAYER SCHERING PHARMA AG

BIOGENIDEC

BIOIBERICA

BIOMET

BIOTIE THERAPIES

BMS

BOEHRINGER INGELHEIM

BONE MEDICAL, LTD.

CAPSITONIN ORAL CALCITONIN

ORAL PARATHYROID HORMONE BN003

TNF REGULATORS BN006

BONE CELL REGULATOR: BN005 AND BN008

BTG INTERNATIONAL LTD.

CAN-FITE BIOPHARMA

CARTICEPT MEDICAL, INC.

CELGENE CORPORATION

CENTOCOR ORTHO BIOTECH

CEPHALON, INC.

CHELSEA THERAPEUTICS, INC.

CHEMOCENTRYX, INC.

CHUGAI

TABLE 32 CHUGAI H’S PROGRAMS IN DEVELOPMENT FOR BONE AND JOINT DISEASES

 

COMBINATORX, INC.

CRYSTAL GENOMICS

CYTOKINETICS

DELENEX THERAPEUTICS AG

ELAN

ELI LILLY

ESBATECH

EUROFARMA LABS

FERRING PHARMA

FOREST LABS

GENELABS TECHNOLOGIES (GSK)

GENENTECH, INC.

GENMAB A/S

GENZYME

GLAXO WELLCOME U.K., LTD. (GSK)

HALOZYME THERAPEUTICS

HARBOR BIOSCIENCES, INC. (FORMERLY HOLLIS-EDEN)

HORIZON THERAPEUTICS

HUMAN GENOME SCIENCES

HUMANIS KLINIKUM

IDERA PHARMACEUTICALS

IMMUNOMEDICS, INC.

IMMUPHARMA, PLC

INCYTE

IPSEN

ISOTIS ORTHOBIOLOGICS (ACQUIRED BY INTEGRA LIFESCIENCES)

SPINAL FUSION

TRAUMA

JOINT REVISION

BONE VOID FILLING

CRANIOMAXILLOFACIAL SURGERY

ORAL AND PERIODONTAL REPAIR

ITALFARMACO S.P.A.

JOHNSON & JOHNSON

KENSEY NASH

LEXICON PHARMACEUTICALS

MEDAREX

MEDIGENE AG

MEDIMMUNE, LLC

MEDIPOST CO., LTD.

MEDIVIR AB

MIV 710/711 (CATH-K)

MEDTRONIC SOFAMOR DANEK

MERCK

MERRIMACK PHARMACEUTICALS

MERRION PHARMACEUTICALS, LTD.

MITSUBISHI TANABE

MORPHOSYS AG

NEOVACS SA

NICOX SA

NIPPON KAYAKU

NORDIC BIOSCIENCE A/S

NOVARTIS

NOVO NORDISK A/S

NOXXON PHARMA AG

NPS PHARMACEUTICALS

NUON THERAPEUTICS, INC.

NUVO RESEARCH, INC.

NYCOMED

ONO PHARMA

ORTHOVITA

OSTEOLOGIX, INC.

OSTEOTECH

PALAU PHARMA

PANGENETICS BV

PG102-PROTOTYPE

PG102

PASCOE PHARMA

PDL BIOPHARMA, INC.

PFIZER

PHYTOHEALTH CORPORATION

PHN031(PH3)

Description

Development Status

POZEN, INC.

RADIUS HEALTH

REGENERON

RIGEL PHARMA, INC.

RIVEX PHARMA, INC.

ROCHE

SANOFI-AVENTIS

SERVIER

SMITH & NEPHEW PLC

SPINAL RESTORATION, INC.

STRYKER BIOTECH

SUCAMPO PHARMACEUTICALS, INC.

SYNTHES, INC.

TAKEDA

TEVA

TRUBION PHARMACEUTICALS INC.

TRUBION PHARMACEUTICALS INC. (CONTINUED)

UCB

UNIGENE LABS

VERTO MEDICAL, LTD.

WRIGHT MEDICAL TECHNOLOGY INC.

XOMA

ZELOS THERAPEUTICS, INC.

ZELOS THERAPEUTICS, INC. (CONTINUED)

ZIMMER

ZOSANO PHARMA

ZYMOGENETICS, INC.

ATACICEPT (FORMERLY TACI-IG)

AUGMENT BONE GRAFT (FORMERLY GEMOS1TM)/AUGMENT INJECTABLE BONE GRAFT (FORMERLY GEM-OS2TM)

CHAPTER TEN: OUTLOOK—TRENDS AND CHALLENGES

MSDS ARE A LARGE BURDEN ON THE HEALTHCARE SYSTEM

OUTLOOK FOR ORTHOBIOLOGICS IS BRIGHT

OSTEOPOROSIS: PAYER ACCEPTANCE IS KEY ISSUE

COMPETITION FOR THE RA PATIENT POPULATION FAILING ANTI-TNF THERAPIES

LUPUS IS A CHALLENGING INDICATION

DIAGNOSIS RATES FOR PSORIATIC ARTHRITIS AND AS

LIST OF TABLES

SUMMARY TABLE GLOBAL POTENTIAL MARKET FOR

MUSCULOSKELETAL DISEASE, THROUGH 2014 ($ MILLIONS)

TABLE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONIC

MEDICAL CONDITIONS (%)

TABLE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL

DISEASE, THROUGH 2014 ($ MILLIONS)

TABLE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 (%/$

MILLIONS)

TABLE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDING

BIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONS)

TABLE 5 GLOBAL REVENUE OF NSAIDS FOR MSD, 2009 ($ MILLIONS)

TABLE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009

($ MILLIONS)

TABLE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($

MILLIONS)

TABLE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($

MILLIONS)

TABLE 9 GLOBAL SERM MARKET FOR MSD, 2009 ($ MILLIONS)

TABLE 10 GLOBAL PTH MARKET FOR MSD ($ MILLIONS)

TABLE 11 GLOBAL BMP MARKET FOR MSD, 2009 ($

MILLIONS)

TABLE 12 VISCOSUPPLEMENTATION MARKET SHARE BY

PRODUCT, 2009 (%)

TABLE 13 TOP 10 COMPANIES IN MSD MARKET, REVENUE AND

ASSOCIATED GLOBAL MARKET SHARE, 2009 ($ MILLIONS/%)

TABLE 14 SWOT ANALYSIS OF MSD MARKET: NSAIDS

TABLE 15 SWOT ANALYSIS OF MSD MARKET: BIOLOGICALS

TABLE 16 GLOBAL PROJECTED MARKET FOR MSD, BY

APPLICATION, THROUGH 2014 ($ MILLIONS)

TABLE 17 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BY

COMPANY, 2009 (%)

TABLE 18 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BY

MATERIAL TYPE, THROUGH 2014 ($ MILLIONS)

TABLE 19 PROJECTED MARKET FOR KEY MSD PRODUCTS,

THROUGH 2014 ($ MILLIONS)

TABLE 20 TREATMENTS AND MOA

TABLE 21 SIDE EFFECTS

TABLE 22 PREVALENCE OF MAJOR MSDS IN MAJOR GLOBAL

MARKETS, 2009 (%)

TABLE 23 GLOBAL POTENTIAL MARKET FOR TOTAL MSD, THROUGH

2014 ($ MILLIONS)

TABLE 24 KEY OTC TREATMENTS AND NATURAL PRODUCTS

TABLE 25 DRUGS USED TO TREAT MSD

TABLE 26 LEADING MSD THERAPIES AND COST PER DAY (U.S.

DOLLARS)

TABLE 27 VENTURE INVESTMENT IN MSD COMPANIES

TABLE 28 RELATED DEALS AND PARTNERSHIPS

TABLE 29 CLINICAL DEVELOPMENT PIPELINE

TABLE 30 PATENT ANALYSIS

TABLE 31 KEY PATENT HOLDERS IN BONE/JOINT DISEASE AREA

(NUMBER/%)

TABLE 32 CHUGAI H’S PROGRAMS IN DEVELOPMENT FOR BONE

AND JOINT DISEASES

LIST OF FIGURES

SUMMARY FIGURE GLOBAL POTENTIAL MARKET FOR

MUSCULOSKELETAL DISEASE, 2009 AND 2014 ($ MILLIONS)

FIGURE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONIC

MEDICAL CONDITIONS (%)

FIGURE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL

DISEASE, 2009 AND 2014 ($ MILLIONS)

FIGURE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 ($

MILLIONS)

FIGURE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDING

BIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONS

FIGURE 5 GLOBAL REVENUE OF NSAIDS FOR MSD BY DRUG, 2009 ($

MILLIONS)

FIGURE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009

($ MILLIONS)

FIGURE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($

MILLIONS)

FIGURE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($

MILLIONS)

FIGURE 9 GLOBAL BMP MARKET FOR MSD BY COMPANY, 2009 ($

MILLIONS)

FIGURE 10 VISCOSUPPLEMENTATION MARKET SHARE BY

PRODUCT, 2009 (%)

FIGURE 11 TOP 10 COMPANIES IN MSD MARKET BY GLOBAL

MARKET SHARE, 2009 (%)

FIGURE 12 GLOBAL PROJECTED MARKET FOR MSD, BY

APPLICATION, 2006-2014 ($ MILLIONS)

FIGURE 13 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BY

COMPANY, 2009 (%)

FIGURE 14 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BY

MATERIAL TYPE, 2008-2014 ($ MILLIONS)

FIGURE 15 PROJECTED MARKET FOR KEY MSD PRODUCTS, 2008-

2014 ($MILLIONS)

FIGURE 16 KEY PATENT HOLDERS IN BONE/JOINT DISEASE

MARKET (%)